Our group was recently funded by Portugal2020 to develop new therapies for stroke. The project has the contribution of two Hospitals in the Center Region of Portugal (Hospital Rovisco Pais and Hospital da Universidade de Coimbra) and a company (Crioestaminal). Stroke is the second cause of mortality in the world, and patients that survive to the accident present a high probability of morbidity, i.e., neurologic deficit (motor or cognitive). So far, there is only a therapy approved by FDA for the treatment of ischemic stroke, the tissue plasminogen activator (which should be administered until 3 h after stroke), which has several limitations. The present project aims to create an innovative therapeutic platform to treat stroke patients based in stem cells and their products.